Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Stoke Therapeutics Schedule 13G/A (Amend. No. 3) reports that Lynx1 Capital Management and Weston Nichols beneficially own 4,121,244 shares of Stoke Therapeutics common stock, representing 7.0% of the class. The filing cites 59,150,790 shares outstanding as of February 28, 2026 from the company’s Form 10-K.
The disclosure attributes the shares to the Lynx1 Fund and a managed account, shows shared voting and dispositive power over the reported shares, and states that the Lynx1 Fund has the right to receive dividends or sale proceeds. Signatures are by Weston Nichols on behalf of Lynx1 and individually.
Insights
Large passive stake disclosure — useful for ownership monitoring.
The filing lists 4,121,244 shares and a 7.0% ownership stake based on February 28, 2026 outstanding shares. This identifies Lynx1 as a meaningful holder whose future filings could affect reported concentration metrics.
Impact depends on whether the position is long-term; this Schedule 13G/A framework signals passive intent rather than activist pursuit. Subsequent amendments or Form 13D/F would change that characterization.
Filing follows beneficial ownership disclosure rules for >5% holders.
The statement attributes shared voting and dispositive power and notes the Lynx1 Fund’s right to dividends and sale proceeds. The filing includes required issuer and filer addresses, CUSIP 86150R107, and signatures dated May 15, 2026.
Compliance implications: monitor for any future conversion to a 13D or open-market transactions that would require different disclosure treatment in subsequent SEC filings.
Key Figures
Beneficially owned shares:4,121,244 sharesPercent of class:7.0%Shares outstanding:59,150,790 shares+2 more
5 metrics
Beneficially owned shares4,121,244 sharesAmount reported by Lynx1 and Weston Nichols
Percent of class7.0%Calculated using outstanding shares as of Feb 28, 2026
Shares outstanding59,150,790 sharesOutstanding shares as of <date>February 28, 2026</date> from Form 10-K
CUSIP86150R107Stoke Therapeutics common stock identifier
Filing signature dateMay 15, 2026Date signatures by Weston Nichols appear
"This statement is filed by: Lynx1 Capital Management LP"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownershipregulatory
"Amount beneficially owned: The information required by Item 4(a)"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared dispositive powerfinancial
"Shared Dispositive Power 4,121,244.00"
Fund-managed accountfinancial
"directly held by the Lynx1 Fund and the managed account"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Lynx1 Capital Management hold in Stoke Therapeutics (STOK)?
Lynx1 Capital Management reports beneficial ownership of 4,121,244 shares, representing 7.0% of common stock. The percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026 per the company’s Form 10-K.
Does the filing show who controls voting or sale decisions for the shares?
The filing shows shared voting power and shared dispositive power of 4,121,244 shares. It states the Lynx1 Fund has the right to receive dividends or proceeds from sales of the reported shares.
What filing form was used to disclose this ownership and why?
This is a Schedule 13G/A (Amendment No. 3), which is used to report ownership by a person or entity that may qualify as a passive investor holding more than 5% of a class of equity. It reports beneficial ownership and voting/dispositive powers.
When were the signatures and filing dated for this Schedule 13G/A?
The filing is signed by Weston Nichols on behalf of Lynx1 Capital Management GP LLC and individually, with signature dates of May 15, 2026. The ownership percentage uses an outstanding share count as of February 28, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
Stoke Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
86150R107
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Lynx1 Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,121,244.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,121,244.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,121,244.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Weston Nichols
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,121,244.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,121,244.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,121,244.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Stoke Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
45 Wiggins Ave, Bedford, Massachusetts 01730.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund") and a managed account, with respect to the common stock par value $0.0001 per share ("Common Stock"), of Stoke Therapeutics, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund and the managed account; and
(ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Lynx1 Fund and the managed account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
Weston Nichols
c/o Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
(c)
Citizenship:
Investment Manager - Delaware
Mr. Nichols - United States of America
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
86150R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 59,150,790 shares of Common Stock outstanding as of February 28, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 16, 2026.
(b)
Percent of class:
7.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Lynx1 Capital Management LP
Signature:
/s/ Weston Nichols
Name/Title:
By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
